| 摘要 |
Compounds of formula (1); wherein R<SUB>1 </SUB>is optionally substituted C<SUB>1</SUB>-C<SUB>3</SUB>alkyl C<SUB>2</SUB>-C<SUB>3</SUB>alkenyl, or C<SUB>2</SUB>-C<SUB>3</SUB>alkynyl, or -NR<SUB>6</SUB>R<SUB>1</SUB>, -ORB, -SR<SUB>9 </SUB>or halogen; R<SUB>3 </SUB>is II; optionally substituted C,-Csalkyl, C<SUB>2</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>2</SUB>C<SUB>6</SUB>alkynyl, or C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl, halogen; OH or OR<SUB>10</SUB>; R<SUB>4 </SUB>is H, optionally substituted C<SUB>1</SUB>C<SUB>6</SUB>alkyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkynyl, C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl, aryl or heteroaryl, R<SUB>5 </SUB>is H or Optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkynyl, or C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl; or R<SUB>4 </SUB>and R<SUB>5 </SUB>together form a 5 or 6-membered heterocyclic ring; and R<SUB>7</SUB>, R<SUB>8</SUB>, R<SUB>9 </SUB>and R<SUB>10 </SUB>are optionally substituted C<SUB>1</SUB>-C<SUB>3</SUB>alkyl, C<SUB>2</SUB>-C<SUB>3</SUB>alkenyl, C<SUB>2</SUB>-C<SUB>3</SUB>alkynyl, or C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.
|
